Gene symbol | Predicted SNP impact | Predicted SNP effect | Detected mutation | Gene’s implication in cancer prognosis/progression | |
---|---|---|---|---|---|
MIA3 | High | Stop gained | c.2335A>T | p.Lys779* | Â |
BTLA | High | Stop gained | c.94G>T | p.Glu32* | Â |
SAMD9 | High | Stop gained | c.2827G>T | p.Gly943* | Â |
ARMCX2 | High | Stop gained | c.1055C>A | p.Ser352* | Â |
WDFY3 | High | Stop gained | c.7504C>T | p.Gln2502* | Â |
SEMA6A | High | Stop gained | c.270T>A | p.Tyr90* | Benign prognostic factor in glioblastoma [53] |
ALDH5A1 | High | Structural interaction variant | c.844T>C | p.Phe282Leu | Benign prognostic factor in high-grade serous ovarian carcinoma [54] |
ARHGDIA | High | Structural interaction variant | c.573C>A | p.Ser191Ser | Benign prognostic factor in glioma [55] |
MAPKBP1 | High | Stop gained | c.3268G>T | p.Glu1090* | Â |
SORCS1 | Moderate | Missense variant | c.2303G>A | p.Gly768Glu | Â |
RAG1 | Moderate | Missense variant | c.2023C>A | p.Leu675Met | Â |
NEUROD4 | Moderate | Missense variant | c.204G>T | p.Lys68Asn | Â |
NALCN | Moderate | Missense variant | c.2091T>G | p.Ile697Met | Somatic mutations in pancreatic ductal adenocarcinomas [64] |
AHNAK2 | Moderate | Missense variant | c.12994G>A | p.Val4332Met | Correlates with poor prognosis in pancreatic ductal adenocarcinomas [65] |
MYO9A | Moderate | Missense variant | c.4708G>C | p.Glu1570Gln | Â |
CHD2 | Moderate | Missense variant | c.595C>T | p.Arg199Cys | Â |
CNTNAP1 | Moderate | Missense variant | c.2109C>G | p.Phe703Leu | Â |
NLRP5 | Moderate | Missense variant | c.2448G>A | p.Met816Ile | Â |
HEATR5B | Moderate | Missense variant | c.307G>T | p.Asp103Tyr | Â |
SPTBN1 | Moderate | Missense variant | c.5222G>T | p.Arg1741Leu | Â |
TTC3 | Moderate | Missense variant | c.3788G>C | p.Arg1263Thr | Â |
ZNF502 | Moderate | Missense variant | c.503C>T | p.Ser168Leu | Â |
CRYBG3 | Moderate | Missense variant | c.1753A>G | p.Lys585Glu | Â |
BMP3 | Moderate | Missense variant | c.845C>A | p.Ser282Tyr | Â |
TREML2 | Moderate | Missense variant | c.496A>C | p.Met166Leu | Â |
DPYD | Moderate | Missense variant | c.384G>T | p.Met128Ile | Â |
RASAL2 | Moderate | Missense variant | c.199C>T | p.Arg67Trp | Â |
CFAP46 | Moderate | Missense variant | c.1333G>T | p.Ala445Ser | Â |
CEP83 | Moderate | Missense variant | c.380A>G | p.Glu127Gly | Â |
TSPOAP1 | Moderate | Missense variant | c.3004C>A | p.Pro1002Thr | Â |
ZNF761 | Moderate | Missense variant | c.1492G>C | p.Glu498Gln | Â |
PAXIP1 | Moderate | Missense variant | c.2004A>T | p.Arg668Ser | Â |
RP1 | Moderate | Missense variant | c.5123C>A | p.Ala1708Asp | Somatic mutations in intramedullary spinal cord ependimomas [66] |
NCOA2 | Moderate | Missense variant | c.3320G>T | p.Ser1107Ile | Frequently amplified in breast cancer [67] |
GLYR1 | Moderate | Missense variant | c.1336G>C | p.Ala446Pro | Â |
DNAAF4 | Moderate | Missense variant | c.572A>G | p.Glu191Gly | Â |
CYP3A43 | Moderate | Missense variant | c.1154T>C | p.Leu385Ser | Â |
LRP4 | Moderate | Missense variant | c.4798C>T | p.Leu1600Phe | Â |
F11 | Moderate | Missense variant | c.1654C>A | p.His552Asn | Â |
CCDC166 | Moderate | Missense variant | c.67G>C | p.Ala23Pro | Â |
ANKRD22 | Moderate | Missense variant | c.1253G>A | p.Arg418Gln | Correlates with relapse and short overall survival in non-small cell lung cancer [68] |
REM1 | Moderate | Missense variant | c.188C>T | p.Pro63Leu | Â |
PCSK1 | Moderate | Missense variant | c.1270C>G | p.Pro424Ala | Â |